| References: |
Fidaxomicin (trade names Dificid, Dificlir, and previously OPT-80 and PAR-101) is the first in a new class of narrow spectrum macrocyclic antibiotic drugs. It is a fermentation product obtained from the actinomycete Dactylosporangium aurantiacum subspecies hamdenesis. Fidaxomicin is non-systemic, meaning it is minimally absorbed into the bloodstream, it is bactericidal, and it has demonstrated selective eradication of pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora. The maintenance of normal physiological conditions in the colon can reduce the probability of Clostridium difficile infection recurrence. For the detailed information about the solubility of Fidaxomicin (Dificid) in water, the solubility of Fidaxomicin (Dificid) in DMSO, the solubility of Fidaxomicin (Dificid) in PBS buffer, the animal experiment（test） of Fidaxomicin (Dificid),the in vivo,in vitro and clinical trial test of Fidaxomicin (Dificid),the cell experiment（test） of Fidaxomicin (Dificid),the IC50, EC50 and Affinity of Fidaxomicin (Dificid), please contact DC Chemicals. |
